Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

Campbell, 2011, Update on malignant pleural mesothelioma, Semin Respir Crit Care Med, 32, 102, 10.1055/s-0031-1272874

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

Ceresoli, 2011, Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma, Lung Cancer, 72, 73, 10.1016/j.lungcan.2010.12.004

Hicklin, 2005, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J Clin Oncol, 23, 1011, 10.1200/JCO.2005.06.081

Roskoski, 2007, Vascular endothelial growth factor (VEGF) signaling in tumor progression, Crit Rev Oncol Hematol, 62, 179, 10.1016/j.critrevonc.2007.01.006

Loganathan, 2011, Role of protein kinase C beta and vascular endothelial growth factor receptor in malignant pleural mesothelioma: therapeutic implications and the usefulness of Caenorhabditis elegans model organism, J Carcinog, 10, 4, 10.4103/1477-3163.77274

Kindler, 2012, Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma, J Clin Oncol, 30, 2509, 10.1200/JCO.2011.41.5869

Kao, 2011, The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine, Lung Cancer

Wedge, 2005, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer, Cancer Res, 65, 4389, 10.1158/0008-5472.CAN-04-4409

Drevs, 2007, Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors, J Clin Oncol, 25, 3045, 10.1200/JCO.2006.07.2066

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059

Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9

Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452

Robinson, 2010, Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker, Semin Nephrol, 30, 591, 10.1016/j.semnephrol.2010.09.007

Bono, 2009, Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma, Ann Oncol, 20, 393, 10.1093/annonc/mdn729

Schneider, 2008, Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100, J Clin Oncol, 26, 4672, 10.1200/JCO.2008.16.1612

Scartozzi, 2009, Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab, Ann Oncol, 20, 227, 10.1093/annonc/mdn637

Dahlberg, 2010, Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599, J Clin Oncol, 28, 949, 10.1200/JCO.2009.25.4482

Garland, 2011, Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509, J Thorac Oncol, 6, 1938, 10.1097/JTO.0b013e318229586e

Kindler, 2001, SU5416 in malignant mesothelioma: a University of Chicago Phase II Consortium Study, J Clin Oncol, 20, 1359

Baas, 2005, Thalidomide in patients with malignant pleural mesothelioma, Lung Cancer, 48, 291, 10.1016/j.lungcan.2004.10.005

Nowak, 2010, Final results of a phase II trial of sunitinib as second-line therapy in malignant pleural mesothelioma, J Clin Oncol, 28, 7036, 10.1200/jco.2010.28.15_suppl.7036

Dubey, 2010, A phase II study of sorafenib in malignant mesothelioma: results of cancer and leukemia group B 30307, J Thorac Oncol, 5, 1655, 10.1097/JTO.0b013e3181ec18db

Jahan, 2012, Vatalanib in malignant mesothelioma: a Phase II trial by the cancer and leukemia group b (CALGB 30107), Lung Cancer, 76, 393, 10.1016/j.lungcan.2011.11.014